Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting

2006 ◽  
Vol 23 (3) ◽  
pp. 150-160 ◽  
Author(s):  
Åsa K. Wallin ◽  
Niels Andreasen ◽  
Sture Eriksson ◽  
Stellan Båtsman ◽  
Birgitta Näsman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Setting ◽  
Routine Clinical Setting

Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

2012 ◽  
Vol 9 (4) ◽  
pp. 406-413 ◽  
Author(s):  
Julien Dumurgier ◽  
Olivier Vercruysse ◽  
Claire Paquet ◽  
Stéphanie Bombois ◽  
Chloé Chaulet ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Setting ◽  
Disease Biomarkers

P4-314: Discordance Between Amyloid-PET and CSF Amyloid-β for Diagnosing Alzheimer’S Disease in a Clinical Setting

2016 ◽  
Vol 12 ◽  
pp. P1154-P1154
Author(s):  
Ellis Niemantsverdriet ◽  
Tobi Van den Bossche ◽  
Sara Van Mossevelde ◽  
Julie Ottoy ◽  
Jeroen Verhaeghe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Setting ◽  
Amyloid Β ◽  
Amyloid Pet

Diagnosis of Preclinical Alzheimer's Disease in a Clinical Setting

2001 ◽  
Vol 13 (4) ◽  
pp. 411-423 ◽  
Author(s):  
Pieter Jelle Visser ◽  
Frans R. J. Verhey ◽  
Rudolf W. H. M. Ponds ◽  
Jellemer Jolles
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Clinical Setting ◽  
Global Deterioration Scale ◽  
Delayed Recall ◽  
Clinical Criteria ◽  
Preclinical Ad ◽  
State Examination

Introduction. The aim of the study was to investigate whether the preclinical stage of Alzheimer's disease (AD) can be diagnosed in a clinical setting. To this end we investigated whether subjects with preclinical AD could be differentiated from subjects with nonprogressive mild cognitive impairment and from subjects with very mild AD-type dementia. Methods. Twenty-three subjects with preclinical AD, 44 subjects with nonprogressive mild cognitive impairment, and 25 subjects with very mild AD-type dementia were selected from a memory clinic population. Variables that were used to differentiate the groups were demographic variables, the Mini-Mental State Examination score, performance on cognitive tests, measures of functional impairment, and measures of noncognitive symptomatology. Results. Age and the scores for the delayed recall task could best discriminate between subjects with preclinical AD and subjects with nonprogressive mild cognitive impairment. The overall accuracy was 87% The score on the Global Deterioration Scale and a measure of intelligence could best discriminate between subjects with preclinical AD and subjects with very mild AD-type dementia. The overall accuracy was 85% Conclusions. Subjects with preclinical AD can be distinguished from subjects with nonprogressive mild cognitive impairment and from subjects with very mild AD-type dementia. This means that preclinical AD is a diagnostic entity for which clinical criteria should be developed.

Critical Comparison of Different Biomarkers for Alzheimer’s Disease in a Clinical Setting

2015 ◽  
Vol 48 (2) ◽  
pp. 425-432 ◽  
Author(s):  
David Weise ◽  
Solveig Tiepolt ◽  
Carolin Awissus ◽  
Karl-Titus Hoffmann ◽  
Donald Lobsien ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Setting ◽  
Critical Comparison

scholarly journals The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting

2017 ◽  
Vol 60 (2) ◽  
pp. 561-576 ◽  
Author(s):  
Ellis Niemantsverdriet ◽  
Julie Ottoy ◽  
Charisse Somers ◽  
Ellen De Roeck ◽  
Hanne Struyfs ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Clinical Setting ◽  
Amyloid Pet

scholarly journals Recognising Early Symptoms of Alzheimer's Disease in Routine Clinical Practice

2009 ◽  
Vol 4 (2) ◽  
pp. 14
Author(s):  
Sean Knox ◽  
Craig W Ritchie ◽  
◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neuropsychological Testing ◽  
Memory Loss ◽  
Early Symptoms ◽  
Clock Drawing Test ◽  
Early Stages ◽  
Routine Clinical Setting ◽  
Magnetic Resonance Imaging Mri ◽  
State Examination

The prevalence of Alzheimer's disease is expected to significantly increase over the next few decades. Recognising symptoms in the routine clinical setting can be challenging, particularly in the early stages. Memory loss that causes disruption to everyday life may be the first presenting complaint; however, more subtle changes may occur much earlier. These may include difficulty in performing complex activities of daily living, decline in objective neuropsychological testing and apathy, which may be present for a decade before a diagnosis is made. In the non-specialist setting, the Mini Mental State Examination and the clock-drawing test still predominate and there is limited scope for applying tests such as magnetic resonance imaging (MRI) scanning or plasma markers. At present we remain poor at diagnosing Alzheimer's dementia, particularly in the early stages; therefore, improved awareness of early symptoms as well as a belief in the value of early diagnosis may lead to more effective management of patients.

Sign in / Sign up

Export Citation Format

Share Document